For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Hybritech Incorporated

USPTO Granted Patents = 29

% Expired Patents = 3.4

CIPO Patents = 1

Trademarks = 3

Forward Citations = 2,131

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Stephen D Mikolajczyk (6 out of 15 patents)

Robert L Wolfert (5 out of 10 patents)

Mohammad Saeed Saedi (5 out of 7 patents)

4. Gary S David (3 out of 14 patents)

5. Harry G Rittenhouse (3 out of 6 patents)

6. Abhay Kumar (3 out of 4 patents)

7. Clarence Nathaniel Ahlem (3 out of 8 patents)

8. Ann E Huang (3 out of 3 patents)

9. Philip A Levinson (3 out of 3 patents)

10. Tang Jang Wang (2 out of 6 patents)

11. Kristine Kuus-Reichel (2 out of 3 patents)

12. Donald J Tindall (2 out of 5 patents)

13. Charles Y Young (2 out of 5 patents)

14. James M Frincke (2 out of 2 patents)

15. Richard M Bartholomew (2 out of 2 patents)

Core Competencies:

Prostate Specific Antigens

BRCA1 Mutations

Immunoassay Methods

hK2 Polypeptide

Trifunctional Antibodies

Ligand-Receptor Assays

Bone Alkaline Phosphatase

Monoclonal Antibodies

Tumor-Associated Antigens

Protein-Dye Conjugate

Biologically Active Molecules

Immunometric Assays

29 patents: Sort by Forward Citations

1. 7659073 - Forms of prostate specific antigens and methods for their detection (2010-02-09),

2. 7288636 - Forms of prostate specific antigens and methods for their detection (2007-10-30),

3. 6514713 - Methods of detecting BRCA1 mutations (2003-02-04),

4. 6482599 - Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such (2002-11-19),

5. 6284873 - Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex (2001-09-04),

6. 6103237 - Stable variant hK2 polypeptide (2000-08-15),

7. 6093796 - Recombinant hK2 polypeptide (2000-07-25),

8. 6013471 - DNA encoding hK2 variant polypeptides (2000-01-11),

9. 5879881 - Solid phase system for use in ligand-receptor assays (1999-03-09),

10. 5589574 - Assay for bone alkaline phosphatase (1996-12-31),

11. 5525473 - Assay for bone alkaline phosphatase (1996-06-11),

12. 5447838 - Protein-dye conjugate for confirmation of correct dilution of calibrators (1995-09-05),

13. 5439829 - Immobilization of biologically active molecules by changing the (1995-08-08),

14. 5395754 - Membrane-based immunoassay method (1995-03-07),

15. 5273743 - Trifunctional antibody-like compounds as a combined diagnostic and (1993-12-28),

Company Overview

Hybritech Incorporated, based in San Diego, CA, is a pioneering biotechnology company specializing in the development and manufacturing of innovative diagnostic products. The organization focuses on advancing immunoassay technologies, particularly in the fields of oncology and infectious diseases. Hybritech is recognized for its contributions to the medical diagnostics sector, providing essential tools that enhance disease detection and monitoring, thereby improving patient outcomes and supporting healthcare professionals globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

29 Patents

#214 in San Diego, CA

#2,768 in California

#11,631 in US

#22,570 in the World

San Diego, CA, United States of America

Hybritech Incorporated

Forward Citations = 2,131

53 inventors:

Stephen D Mikolajczyk (6 out of 15 patents)

Robert L Wolfert (5 out of 10 patents)

Mohammad Saeed Saedi (5 out of 7 patents)

4. Gary S David (3 out of 14 patents)

5. Harry G Rittenhouse (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hybritech Incorporated. Retrieved from https://idiyas.com/company/hybritech

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…